Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endothelial Protection in Post COVID-19 Patients. The Effect of Sulodexide on Serum Levels of Biomarkers for Endothelial Dysfunction. A Prospective, Randomized, Placebo-controlled, Investigator-initiated Trial

Next Previous
Search
Trial Profile

Endothelial Protection in Post COVID-19 Patients. The Effect of Sulodexide on Serum Levels of Biomarkers for Endothelial Dysfunction. A Prospective, Randomized, Placebo-controlled, Investigator-initiated Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sulodexide (Primary)
  • Indications Thrombosis; Vascular disorders
  • Focus Pharmacodynamics

    • Most Recent Events

    • 01 Jan 2025 Results assessing the impact of sulodexide on serum levels of endothelial dysfunction biomarkers in patients during the convalescent phase of COVID-19 published in the Clinical and Applied Thrombosis/Hemostasis
    • 09 Aug 2024 Status changed from recruiting to completed.
    • 08 Dec 2023 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top